Human Genome Sciences

Contact
hgsi.com
+13013098504

Human Genome Sciences

14200 Shady Grove Road
20850 Rockville
USA
+13013098504
hgsi.com
Contact
Profile Products News
Contact

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company’s primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon® (albinterferon alfa-2b) for hepatitis C and LymphoStat-B® (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

Read more about Human Genome Sciences
Facts about Human Genome Sciences
  • Focus : Manufacturer
  • Industry : Biotechnology

Product portfolio of Human Genome Sciences

Product portfolio

Show all

News about Human Genome Sciences

Human Genome Sciences

06-Oct-2010 | research and development

Novartis discontinues development of two investigational compounds

Strategic focus remains on differentiated products and agents most likely to address unmet patient need

Read news
Human Genome Sciences

23-Aug-2010 | research and development

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta

GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review ...

Read news
Human Genome Sciences

19-Jul-2010 | business & finance

Human Genome Sciences and Lonza enter commercial manufacturing agreement for BENLYSTA

Human Genome Sciences, Inc. (HGS) and Lonza announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under ...

Read news
Human Genome Sciences

21-Jul-2009 | research and development

First Potential Lupus-Specific Treatment in Sight

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the ...

Read news
Human Genome Sciences

11-May-2009 | business & finance

Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement

Human Genome Sciences, Inc. and Novozymes Biopharma, a part of Novozymes, announced that they have amended an existing license agreement to allow both ...

Read news
Human Genome Sciences

15-Aug-2008 | business & finance

Eden Biodesign signs marketing services agreement with human genome sciences

New alliance will increase Human Genome Sciences' global marketing reach for large scale cGMP manufacturing services and provides a seamless range of services for clients from process development to 20,000L scale production

Read news
Human Genome Sciences

20-Mar-2007 | business & finance

MedImmune Leases Human Genome Sciences Facility to Expand Cell Culture Influenza Vaccine Manufacturing Capabilities

MedImmune, Inc. and Human Genome Sciences, Inc. (HGS) announced that they have signed an agreement under which MedImmune will lease a portion of an HGS ...

Read news
Human Genome Sciences

16-Nov-2006 | research and development

Human Genome Science announces positive results of phase 2 clinical trial of Lymphostat-B in systemic lupus

Human Genome Sciences, Inc. announced that the 76-week results of a Phase 2 clinical trial demonstrated that LymphoStat-B(TM) (belimumab) reduced disease ...

Read news
Show more news about Human Genome Sciences

Here you will find Human Genome Sciences